<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867685</url>
  </required_header>
  <id_info>
    <org_study_id>D0970C00008</org_study_id>
    <nct_id>NCT00867685</nct_id>
  </id_info>
  <brief_title>Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation</brief_title>
  <official_title>A Phase I, Randomized, Open Label, 2-Way Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of AZD2624 (Tablet Versus Liquid Suspension) Followed by an Additional Period to Assess the Food Effect on the Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the liquid suspension form of AZD 2624 to a tablet
      form of the same drug. This study will also study the effect of food on the tablet form of
      the drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serial blood draws will be used to measure the plasma levels of AZD2624 for the liquid suspension and the tablet formulation in a fed and fasted state.</measure>
    <time_frame>Seventeen blood draws will be collected during each treatment period for a total of 51 samples for the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be measured by the collection of AEs, ECGs, physical exams, and vital signs.</measure>
    <time_frame>Subjects inquiry on AE daily, ECGs collected at 2 timepoints each period, clinical labs collected at 3 timepoints each period, physical exams completed 3 timepoints each period, and vital signs collected each day of each period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 40 mg (2x20mg tablets) in a fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2624</intervention_name>
    <description>Single dose of 40 mg AZD2624 liquid suspension, PO</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2624</intervention_name>
    <description>Single dose of 40 mg AZD 2624 (2x20mg tablets), PO</description>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers

        Exclusion Criteria:

          -  Donation of plasma or blood products within one month of of screening

          -  Clinically relevant abnormalities in physical examination, vital signs,ECG, clinical
             chemistry, hematology, or urinalysis.

          -  Previous participation in an AD2624 study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvan Hurewitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>April 29, 2009</last_update_submitted>
  <last_update_submitted_qc>April 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Smith, MD, PhD, Senior Medical ScienceDirector Emerging Neuroscience</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

